InfuSystem Holdings Inc(INFU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:00 PM ET (Korea 11/7 06:00)
Full metrics table
| Index | RUT | P/E | 30.44 | EPS (ttm) | 0.45 | Insider Own | 5.61% | Shs Outstand | 20.0M | Perf Week | -2.7% |
| Market Cap | 0.27B | Forward P/E | 23.6 | EPS next Y | 23.4% | Insider Trans | 1.36% | Shs Float | 18.8M | Perf Month | 2.09% |
| Enterprise Value | 0.29B | PEG | 0.82 | EPS next Q | 0.13 | Inst Own | 77.78% | Short Float | 4.33% | Perf Quarter | 12.95% |
| Income | 0.01B | P/S | 1.89 | EPS this Y | 51.61% | Inst Trans | 5.1% | Short Ratio | 6.32 | Perf Half Y | 62.78% |
| Sales | 0.14B | P/B | 4.27 | EPS next 5Y | 28.65% | ROA | 9.28% | Short Interest | 0.81M | Perf YTD | 52.62% |
| Book/sh | 3.2 | P/C | 29.93 | EPS past 3/5Y | 632.25% -17.01% | ROE | 15.78% | 52W High | -6.49% ($14.64) | Perf Year | 33.04% |
| Cash/sh | 0.46 | P/FCF | 16.99 | Sales past 3/5Y | 9.28% 8.05% | ROIC | 10.89% | 52W Low | 87.79% ($7.29) | Perf 3Y | 44.56% |
| Dividend Est. | - | EV/EBITDA | 10.56 | EPS Y/Y TTM | 76.01% | Gross Margin | 56.49% | Volatility(W/M) | 6.4% 4.19% | Perf 5Y | -17.43% |
| Dividend TTM | - | EV/Sales | 1.98 | Sales Y/Y TTM | 2.4% | Oper. Margin | 9.83% | ATR (14) | 0.62 | Perf 10Y | 426.54% |
| Dividend Ex-Date | - | Quick Ratio | 2.39 | EPS Q/Q | 39.15% | Profit Margin | 6.54% | RSI (14) | 52.12 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.68 | Sales Q/Q | 3.02% | SMA20 | -0.77% ($13.8) | Beta | 1.38 | Target Price | $17.5 |
| Payout | - | Debt/Eq | 0.35 | Earnings | 2026/11/5 | SMA50 | 4.46% ($13.11) | Rel Volume | 1.37 | Prev Close | $13.56 |
| Employees | 473 | LT Debt/Eq | 0.35 | EPS/Sales Surpr. | 15.38% 0.82% | SMA200 | 31.02% ($10.45) | Avg Volume(3M) | 0.13M | Price | $13.69 |
| IPO | 2006/6/15 | Option/Short | Yes/Yes | Trades | 1719 | Volume | 176,236 | Change | 0.96% |
💉 InfuSystem Holdings is a US-based healthcare company that provides infusion pumps and medical device services in the areas of oncology, pain management, and wound care. The company operates two business segments: patient services and device solutions, and it is a niche leader in the medical device field with a high market share in the outpatient oncology infusion market in the United States and Canada.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded more than usual. That is 137% of its average volume.
INFU makes money exceptionally well
Of every $100 in sales, $9.83 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +51.6% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,360. Peers typically go for $1,907. Compared with its own 5-year average, it is 80% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -17.4%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 77.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #70 of 140 in the industry
Based on market cap of $273M.
QSI#68 Quantum-Si Incorporated $291M PER - 
CLPT#69 ClearPoint Neuro Inc $276M PER - INFU#70 InfuSystem Holdings Inc $273M PER 30.4 
PROF#71 Profound Medical Corp $263M PER - 
TMCI#72 Treace Medical Concepts Inc $262M PER - 
FAQ
What kind of company is INFU?
INFU belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of INFU?
The market cap of INFU is approximately $273M, ranking 3,753 within its sector.
What is the P/E ratio of INFU?
INFU has a P/E ratio of approximately 30.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for INFU?
INFU has recorded a 52-week high of $14.64 and a low of $7.29.
